OUT OF MIND
Would you like to react to this message? Create an account in a few clicks or log in to continue.
Latest topics
» Research Determines Link Between Air Pollution and Mental Illness
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 11:15 am by PurpleSkyz

» EPISODE 5 LINK
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 11:02 am by PurpleSkyz

» CDC: No Record of Naturally Immune Transmitting COVID-19
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 11:00 am by PurpleSkyz

» Surprised? Pfizer, BioNTech Say Jab for New ‘Omicron’ Strain Ready in 100 days
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 10:55 am by PurpleSkyz

» Pacific Ocean garbage patch is immense plastic habitat
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 10:50 am by PurpleSkyz

» Unvaccinated Sit-In Shuts Down Panera in NYC
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 2:54 am by PurpleSkyz

» Nevada Becomes First State To Impose Surcharge On Unvaccinated Workers
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 2:52 am by PurpleSkyz

» We’ve Only Just Begun To See The Benefits Of The New Surge In Homeschooling
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 2:51 am by PurpleSkyz

» Congressman Introduces Bill to Force FDA to Release Pfizer Documents Within 100 Days, Instead of 55 Years
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 2:49 am by PurpleSkyz

» Pro-Vaxxers Triggered After Country Music Legend Reveals He Won’t Get Vax
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 2:46 am by PurpleSkyz

» It’s Time to Free Leonard Peltier, America’s Longest Serving Political Prisoner
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 2:43 am by PurpleSkyz

» One Year Ago Today: Biden Says COVID Vaccines Won’t Be ‘Mandatory’
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 2:40 am by PurpleSkyz

» Disturbing Confrontation Inside Australia’s ‘Gold Standard’ COVID Internment Camp
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 2:37 am by PurpleSkyz

» Rover to investigate mystery cube-shaped object on the Moon
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 2:25 am by PurpleSkyz

» Twitter Users Freak After Ghislaine Maxwell Matches Suspect Sketch for Madeleine McCann Disappearance
Merck Shuts Down Program After Lackluster Data EmptyYesterday at 1:46 am by PurpleSkyz

» CDC/VAERS Data - thru 11-26-21 Sadly Includes 5-Year-Old that Died 4 Days After Pfizer Shot
Merck Shuts Down Program After Lackluster Data EmptySat Dec 04, 2021 11:07 am by PurpleSkyz

» Biden Launches War on the Unjabbed: “The USA Must Vaccinate the World”
Merck Shuts Down Program After Lackluster Data EmptySat Dec 04, 2021 2:46 am by PurpleSkyz

» Twitter Slaps “Unsafe” Label On American Heart Association mRNA Vaccine Warning
Merck Shuts Down Program After Lackluster Data EmptySat Dec 04, 2021 2:39 am by PurpleSkyz

» California Faces Statewide Mandatory Water Restrictions as Drought Worsens
Merck Shuts Down Program After Lackluster Data EmptySat Dec 04, 2021 2:37 am by PurpleSkyz

» Hawaii under blizzard warning as 12 inches of snow and winds up to 100 mph expected
Merck Shuts Down Program After Lackluster Data EmptySat Dec 04, 2021 2:22 am by PurpleSkyz

» French Citizens Resist Vaccine Passports, Take Over Shopping Mall
Merck Shuts Down Program After Lackluster Data EmptySat Dec 04, 2021 2:19 am by PurpleSkyz

» How to Submit Your Public Comments to the U.S. Government Against Its Vaccine Mandates
Merck Shuts Down Program After Lackluster Data EmptySat Dec 04, 2021 1:02 am by PurpleSkyz





Holistic Alternative
Health Care
by Bridgette Lyn Dolgoff

CONTACT HERE TO SCHEDULE ONLINE SESSIONS
www.https://coe-llc.com

NEW ETSY SHOP FEATURING HERBAL SALVES

NOW MAKING A MEDICATED OIL FOR PEOPLE WHO HAVE PCR DAMAGE
www.https://coe-llc.com










Sway on Out Of Mind:
Sway's Website:
josuemercadoproductions.tk
Buy Me A Coffee:
PayPal:www.paypal.me/swaymerk CashApp:

You are not connected. Please login or register

OUT OF MIND » BREAKING NEWS & HOT TOPICS » COVID-19 » Merck Shuts Down Program After Lackluster Data

Merck Shuts Down Program After Lackluster Data

Go down  Message [Page 1 of 1]

PurpleSkyz

PurpleSkyz
Admin

Merck Shuts Down Program After Lackluster Data Th?id=OIP

Merck Shuts Down Covid Vaccine Program After Lackluster Data
By
Riley Griffin
January 25, 2021, 5:45 AM CST   Updated on  January 25, 2021, 9:02 AM CST  


  • Immune response to candidates is inferior to existing shots
  • Merck to repurpose resources, facilities to Covid-19 therapies



LISTEN TO ARTICLE


Merck & Co. is discontinuing development of its two experimental Covid-19 vaccines after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines.
The U.S. drug giant, which has a history of successfully developing vaccines, had adopted a different strategy from rivals Pfizer Inc., Moderna Inc. and Johnson & Johnson, using a more traditional approach of focusing on shots based on weakened viruses. One, called V590, borrowed technology from Merck’s Ebola inoculation, while the other, V591, is based on a measles vaccine used in Europe.
Both were laggards in the vaccine-development race. Merck finished recruiting the first participants for early-stage safety studies near the end of 2020, when front-runners Pfizer and Moderna were preparing to report late-stage data on their shots’ effectiveness. Merck received interim results from its trials this month.
The results were “disappointing, and a bit of a surprise,” said Nick Kartsonis, senior vice president of clinical research for infectious diseases and vaccines at Merck Research Laboratories. Both shots generated fewer neutralizing antibodies to halt infection than other Covid-19 vaccines, and produced inferior immune responses compared with people who had naturally contracted the coronavirus.

“We didn’t have what we needed to be able to move forward,” Kartsonis said in an interview Sunday. After evaluating the data, Merck’s senior leadership decided to discontinue the programs and divert resources to the company’s efforts to develop Covid-19 treatments.
Merck fell as much as 1.1% as of 9:50 a.m. Monday in New York. The shares lost 9.7% over the past 12 months through Friday’s close.

Covid Vaccine Shortage May Last Months: Johns Hopkins

Vaccine Anxiety

While Merck’s vaccines weren’t expected to be part of the initial immunization push in the U.S., the development comes amid heightened anxiety over vaccine supplies and a sluggish pace of injections. The emergence of new variants of the coronavirus has also raised questions about whether the shots that have been cleared will lose effectiveness as the pathogen mutates.
The failure of Merck’s candidates will also leave it locked out of a market that could eventually be dominated by two of its historic U.S. rivals. Pfizer was the first drugmaker to gain authorization for a Covid vaccine in the U.S., followed closely by Moderna. Johnson & Johnson is expected to publish data in the coming weeks on its vaccine’s efficacy and apply for an emergency-use authorization.
Neither of Merck’s candidates was among the six vaccines in the U.S.’s Operation Warp Speed portfolio, though its leadership watched them closely. The drugmaker and its development partner on V590, the International AIDS Vaccine Initiative, did receive some research funding from the government. Its second candidate, V591, relies on technology first developed by France’s Institut Pasteur. Both of the single-dose candidates were well tolerated in early human studies.
Kenilworth, New Jersey-based Merck will record a charge for the fourth quarter of 2020 for costs related to halting the programs. It didn’t disclose the amount of the charge Monday. The early-stage trial results will be submitted to a peer-reviewed medical journal.

What Bloomberg Intelligence Says



“Merck’s decision to stop the development of its two Covid-19 vaccine candidates may be bad news to a world hungry for doses, but will have limited impact on the company’s prospects, as consensus had nothing penciled in.”
--Sam Fazeli, Pharmaceutical Analyst
Click here to read the research.

Therapeutic Focus

A continuing surge in infections has highlighted the need for more treatment options. Merck will steer resources toward two drugs it has in late-stage development to combat the disease, according to Kartsonis.
Read More: Merck-U.S. Deal for Covid Drug Shows Need for Therapies Persist
“In the world of pharmaceutical development, a quick kill is not a bad thing because it allows you to reposition and repurpose your assets,” he said.

Several of Merck’s vaccine manufacturing facilities are being re-tooled to produce one of its Covid-19 drug candidates, MK-7110, which is complex and difficult to manufacture at mass scale. In an interim study, the intravenous therapy significantly improved the likelihood and speed of recovery for severe and critical Covid-19 patients needing oxygen, reducing the risks of respiratory failure and death by more than 50%. Full study results are expected in the first quarter.
Merck’s executives expect U.S. regulators will grant an emergency-use authorization for the drug following those results, and Kartsonis said it could reach sick patients by the middle of the year. The U.S. has already agreed to pay $365 million for 60,000 to 100,000 doses.

Antiviral Pill


The day's biggest storiesGet caught up with the Evening Briefing.
Email


By submitting my information, I agree to the Privacy Policy and Terms of Service and to receive offers and promotions from Bloomberg.

Merck is also working on a pill for Covid-19 patients at earlier stages of the disease. Known as molnupiravir, the antiviral therapy was discovered by scientists at Emory University and is being studied in late-stage trials in both hospital and outpatient settings. Merck and partner Ridgeback Biotherapeutics LP expect to have initial data on the drug’s effectiveness in the first quarter, and to wrap up studies in May, the company said in a statement.
Chief Marketing Officer Michael Nally said in December that Merck expects a regulatory clearance shortly after the company reports data, should it prove successful.
Read More: Single Rolodex Helps Operation Warp Speed Live Up to Its Name
The antiviral is intended to be taken twice a day over five days, for a total of ten capsules. Merck anticipates it will be able to produce more than 20 million courses of the treatment, or 200 million capsules, in 2021, Nally said.
The slow vaccine rollout shows that a need for therapeutics will persist, Kartsonis said, and the drugs could work against future viruses.

https://www.bloomberg.com/news/articles/2021-01-25/merck-shuts-down-covid-vaccine-program-after-lackluster-data?srnd=coronavirus&fbclid=IwAR0Zfi1eAkqMYsuGpFRCON6W4rjs4fXaBfNqr4RJY8T9kOGxxV75y4KzFT0

Thanks to: https://www.bloomberg.com



  

Back to top  Message [Page 1 of 1]

Permissions in this forum:
You cannot reply to topics in this forum